Clinical Trial Update: Study of Telitacicept in Patients With Refractory IgA Nephropathy [Phase 2, Phase 3]

View source ↗

Summary

Phase 2/Phase 3 clinical trial update for telitacicept in refractory IgA nephropathy; status not yet recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Iga Nephropathy

Drugs mentioned

• Telitacicept

Snippet

Sponsor: Second Affiliated Hospital, School of Medicine, Zhejiang University | Conditions: IgA Nephropathy | Phase 2, Phase 3 | Status: NOT_YET_RECRUITING